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Abstract
Overexpression of matriptase has been reported in a variety of human cancers and is sufficient to trigger tumor formation in
mice, but the importance of matriptase in breast cancer remains unclear. We analysed matriptase expression in 16 human
breast cancer cell lines and in 107 primary breast tumors. The data revealed considerable diversity in the expression level of
this protein indicating that the significance of matriptase may vary from case to case. Matriptase protein expression was
correlated with HER2 expression and highest expression was seen in HER2-positive cell lines, indicating a potential role in
this subgroup. Stable overexpression of matriptase in two breast cancer cell lines had different consequences. In MDA-MB-
231 human breast carcinoma cells the only noted consequence of matriptase overexpression was modestly impaired
growth in vivo. In contrast, overexpression of matriptase in 4T1 mouse breast carcinoma cells resulted in visible changes in
morphology, actin staining and cell to cell contacts. This correlated with downregulation of the cell-cell adhesion molecule
E-cadherin. These results suggest that the functions of matriptase in breast cancer are likely to be variable and cell context
dependent.
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Introduction
Matriptase (also known as MT-SP1, ST14, TADG-15 and
epithin) is a member of the family of type II transmembrane serine
proteases [1]. It is an 80–90 kDa glycoprotein with complex
structure, regulatory mechanisms and functions [2,3]. It consists of
a cytoplasmic N-terminus of unknown function, a short trans-
membrane part, and a large C-terminal region containing
a catalytic serine-protease domain and several non-catalytic
domains (a single SEA, two CUB and four LDLRA domains).
Matriptase is synthesized as an inactive single-chain zymogen on
the rough endoplasmic reticulum and travels to the plasma
membrane via the Golgi apparatus [2]. The extracellular part of
matriptase can also be shed from the cell surface into the
surrounding microenvironment. The mechanisms that trigger the
activation of matriptase as well as the details of the activation and
the shedding processes remain incompletely understood. It is
believed that full matriptase activation requires two sequential
endoproteolitic cleavages and transient interaction with its cellular
inhibitor HAI-1 [2,4]. Recent evidence indicates that activation of
matriptase can occur both on the cell surface and inside the cells
and may be an early response to acidosis [5].
Matriptase is important for maintaining epithelial integrity and
mice deficient in this protein die within 48h after birth due to
compromised epidermal barrier function [6]. The spectrum of
known matriptase substrates includes extracellular matrix proteins
[3,7], cell adhesion molecules [8], ion channels [9], growth-factor-
like proteins [10,11] and other proteases [12]. Its actions can result
in protein processing, activation or degradation. Importantly,
there is a large body of evidence implicating matriptase in tumour
formation and metastasis [3,7]. Even low level overexpression of
matriptase is sufficient to trigger tumor formation in mice [13]. In
addition, there is significant evidence linking matriptase to
carcinogenesis in several cancer types including ovarian, prostate
and cervical cancers [3,14]. Consequently, there is considerable
activity in the development of matriptase inhibitors [15,16,17],
and methods to monitor matriptase activity in tumors [18,19].
Although matriptase was originally discovered as a matrix-
degrading protease in breast cancer cells [20], its significance and
role(s) in breast cancer remain poorly understood. Hence, the
validity of matriptase as a target in breast cancer therapy remains
to be established. There are only a few published studies that have
attempted to address the importance of matiptase in breast cancer
and no robust conclusions have emerged (see discussion for further
information). We analysed matriptase expression in 16 human
breast cancer cell lines and in 107 primary breast tumors using
reverse phase protein arrays. We also studied the consequences of
overexpressing matriptase in two breast cancer cell lines. Our
results show that although some cancer cell lines and primary
tumors do express matriptase at relatively high levels, a significant
proportion do not express matriptase at all, or at subdetectable
levels. Matriptase expression was not significantly associated with
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node status, grade or tumor size. Morover, overexpression of
matriptase in MDA-MB-231 and 4T1 cells had different
phenotypic consequences implying that the function(s) of ma-
triptase in breast cancer cells are variable.
Results
Expression of matriptase in breast cancer cell lines
High expression level of matriptase is a consistent feature of
multiple human tumors of epithelial origin, but the amount of data
available on the abundance of this protein in breast cancers
remains relatively scarce. We analysed the expression of
matriptase at the protein level in multiple established human
breast cancer cell lines using reverse phase protein arrays (RPPA)
[21]. To be sure that the RPPA data truthfully reflected matriptase
expression levels in the samples, we independently confirmed them
using standard western blotting approach with a different batch of
antibody and a different signal detection system (see Materials and
Methods for details). As shown in Fig. 1A and Fig. S1 there was
a very good correlation between the results obtained using RPPA
and classical western blotting approach. Out of 16 breast cancer
cell lines tested, seven did not express detectable levels of
matriptase (,44%; BT549, HBL100, MDA-MB-231, MDA-
MB-157, MDA-MB-436, HS578T and HCC1569) and nine
showed detectable expression of this protein (,56%; ZR751,
MCF7, MDA-MB-361, MDA-MB-453, BT474, MDA-MB-468,
HCC1954, SKBR3 and T47D). There was significant diversity in
the expression levels of matriptase among those breast cancer cell
lines that did show detectable levels of the protein, with T47D cells
displaying at least a few times higher level than any other cell line
tested. Interestingly, the majority of the breast cancer cell lines
with detectable matriptase expression showed higher levels of the
protein than the non-tumorigenic breast epithelial cell line
MCF10A used as a control [22], and the HER2 positive cell lines
SKBR3, BT474, and T47D all showed high expression of
matriptase.
The results described above demonstrated that breast cancer
cell lines can be divided into two categories based on matriptase
protein level: (i) those that display significant amounts of the
protein, and (ii) those with no detectable matriptase protein
expression. In an attempt to understand the reasons for this
diversity we employed a bioinformatics-based approach. We
analysed matriptase mRNA expression in the same 17 cell lines
using raw data provided by Neve et all [23] and RMA algorithm
combined with an updated microarray annotation [24]. As
illustrated in Fig. 1B, all the cell lines that displayed undetectable
matriptase protein levels also showed neglectable amounts of
matriptase mRNA. This indicated that downregulation of
matriptase in those cell lines was associated with pre-translational
rather than post-translational mechanisms. There was no clear
quantitative relationship between the amount of matriptase
mRNA and matriptase protein levels in the remaining cell lines
(compare Fig. 1A and Fig. 1B).
Expression of matriptase in primary breast tumors
The results obtained using breast cancer cell lines confirmed the
utility of RPPA approach to determine matriptase protein levels.
We also analysed matriptase expression in protein lysates from 107
primary breast tumor biopsies spotted on the same arrays as the
cell line lysates. Patient details are shown in Table S1. Analysis of
the data revealed that primary tumor samples displayed consider-
able diversity in matriptase protein level reflecting the variability
observed among the cell lines (Fig. 2). There were no significant
correlations between matriptase expression and tumor node status,
grade or size (data not shown). However, matriptase expression
measured was higher in HER2 expressing tumors compared to
HER2 negative (immunohistochemical score 0) tumors (183.8 vs
157.0, p = 0.121, student’s T-test). In order to further explore this
association, HER2 expression was measured quantitatively using
RPPA (data not shown). There was a good correlation between
HER2 and matriptase expression (Spearman’s Rho 0.57,
p,0.001), indicating that matriptase expression is higher in
HER2-positive tumors.
Figure 1. Analysis of matriptase mRNA and protein levels in
a panel of 16 human breast cancer cell lines and a non-
tumorigenic breast epithelial cell line MCF10A. (A) Matriptase
protein levels in indicated cell lines as determined using reverse phase
protein arrays (RPPA). (B) Matriptase mRNA expression levels in
indicated cell lines based on the data from Array Express (E-TABM-
157). The ‘‘cut off’’ line in (A) was set at the value registered for the
MDA-MB-436 cells. These cells displayed the highest RPPA read-out
from all the cell lines that showed no detectable matriptase expression
as validated by western blots presented in Fig. S1. Therefore the line
represents the highest registered background reading. The ‘‘cut off’’ for
Matriptase mRNA expression levels shown in (B) was determined using
statistical information from the expression arrays. For some cell lines the
level of expression was called as not significant above background (or
‘‘Absent’’). The ‘‘cut off’’ was set to the expression level of the highest
‘‘Absent’’ cell line (HCC1569). Error bars represent standard deviations.
doi:10.1371/journal.pone.0034182.g001
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Consequences of matriptase overexpression in MDA-MB-
231 human breast carcinoma and 4T1 mouse breast
carcinoma cells in vitro
The data obtained using protein arrays indicated that
expression of matriptase in breast cancers is rather heterogenous
with some tumors displaying high levels of the protein, and others
showing no detectable levels. This could imply that matriptase
may have diverse functional consequences and its roles in breast
tumorigenesis may depend on cellular context. We decided to
investigate this possibility by overexpressing matriptase in two
breast carcinoma cell lines with different characteristics: (i) MDA-
MB-231 human breast carcinoma cells [25], and (ii) 4T1 mouse
breast carcinoma cells [26]. The MDA-MB-231 cells represent
a well characterised breast cancer model system and are part of the
NCI-60 human cancer cell line panel. The 4T1 cells were selected
as a second model because they show low level of endogenous
matriptase (Fig. 3), and display epithelial rather than mesenchy-
mal morphology. This is in contrast to available human breast
cancer cell lines devoid of matriptase that display mesenchymal-
type morphology [27].
As illustrated in Fig. 4B and Fig. 5B we were able to establish
matriptase overexpressing clones in both cellular backgrounds.
Importantly, matriptase in the established clones seemed to
undergo expected trafficking and posttranslational processing as
demonstrated by the fact that shed matriptase could be detected
extracellulary in the conditioned medium from those cells (Fig. 4C
and Fig. 5C).
Shedding and release of matriptase from cell surface into
conditioned medium is a typical feature of breast cancer cells that
naturally express this protease [28].
As shown in Fig. 4, even relatively high level overexpression of
matriptase in MDA-MB-231 cells had no visible effects on cellular
morphology (Fig. 4A) or actin cytoskeleton organisation (Fig. 4E).
We also could not detect any matriptase-caused effects on in vitro
growth, migration or adhesion in this cellular background (Fig. 4D
and Fig. S2). In contrast, matriptase overexpression in 4T1 cells
at a level comparable to that observed in human breast cancer cell
lines (Fig. 5B), was sufficient to trigger obvious phenotypical
changes. Distinct from cells transfected with the control plasmid,
the majority of matriptase transfected 4T1 cells displayed a more
rounded phenotype (Fig. 5A). Importantly, the maintenance of
this rounded phenotype seemed to require continuous expression
of high levels of matriptase because the cells that spontaneously
reverted to a more flat morphology displayed significant reduction
in matriptase overexpression level (Fig. S3). The rounded
phenotype was associated with changes in the actin cytoskeleton
and much less pronounced cell-cell contacts (Fig. 5A, E). We did
not notice any consistent effects of matriptase overexpression on in
vitro proliferation or migration of selected 4T1 cell clones (Fig. 5D
and Fig. 6A), but the cells that overexpressed matriptase were
much easier to detach from the tissue culture dish than their empty
vector-transfected counterparts (Fig. 6B). This suggested that in
Figure 2. Analysis of matriptase protein levels in a panel of 107 primary tumor biopsies from Edinburgh Breast Cancer Unit. The
samples were spotted on the same slides as cell lines in Fig. 1 and the ‘‘cut off’’ line is placed at identical value as in Fig. 1A. Error bars represent
standard deviations.
doi:10.1371/journal.pone.0034182.g002
Figure 3. Matriptase (MT-SP1) protein levels in MDA-MB-231
and 4T1 cells as compared to human MDA-MB-468 cells (A),
and primary mice keratinocytes (B). Tubulin represents the loading
control.
doi:10.1371/journal.pone.0034182.g003
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the 4T1 cellular background matriptase overexpression may affect
cell adhesion. To address this possibility we first analysed the status
of the non-receptor tyrosine kinase c-Src and focal adhesion kinase
(FAK) – two of the key regulators of actin dynamics and cell-
extracellular matrix adhesions [29]. As shown in Fig. S4,
although there were some differences in the intracellular
distribution of FAK and phosphorylated form of Src between
matriptase overexpressing clones and control clones (perhaps
reflecting the observed differences in the organisation of the actin
cytoskeleton), there were no significant differences in the total
protein levels of FAK and c-Src, or in the levels of phosphorylation
of these proteins at the major regulatory sites (P-FAK Y397 and P-
Src Y416 respectively). We subsequently analysed the effects of
matriptase overexpression on the key cell-cell adhesion molecule
E-cadherin. E-cadherin controls epithelial morphology and is
often lost or internalised during epithelial-mesenchymal transition,
a process that has been implicated in tumor progression and
metastasis [30]. As illustrated in Fig. 6B we found a reduction in
Figure 4. Properties of the MDA-MB-231 cells engineered to overexpress matriptase (MT-SP1 A, MT-SP1 B) and the respective
control clones (Empty A, Empty B). (A) Bright field images of the selected clones and parental cells. (B) Western blots performed on total cell
lysates, and (C) proteins precipitated from conditioned medium, using matriptase specific antibody. (D) In vitro growth curves for the selected clones
and the parental cell line. There were no significant differences between the clones (p.0.05). (E) Representative fluorescence images of MT-SP1 B and
Empty A cells stained with fluorescein-labelled phalloidin (actin cytoskeleton) and DAPI (nuclei). Similar results were obtained with MT-SP1 A and
Empty B clones. Scale bar 10 mm.
doi:10.1371/journal.pone.0034182.g004
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E-cadherin protein levels in cells overexpressing matriptase as
compared to control cells. In addition, immunofluorescence
demonstrated that E-cadherin in matriptase overexpressing cells
was located in intracellular structures rather than at the cell
surface (Fig. 6B). We also found a slight reduction in protein level
and shift in intracellular distribution of bcatenin, an important
mediator of the Wnt signalling and link between E-cadherin and
the actin cytoskeleton at adherens junctions [31]. Whereas in
control cells majority of bcatenin was localized at the plasma
membrane, in matriptase overexpressing clones significant fraction
of bcatenin could be also found in cytoplasmic structures (Fig. 6D
and Fig. S5). Taken together these results suggest that over-
expression of matriptase affects cell-cell interactions in 4T1 cells,
perhaps by influencing E-cadherin/bcatenin protein level and
localization.
Effects of matriptase overexpression on in vivo growth of
MDA-MB-231 and 4T1 cells in an orthotopic xenograft
model
The experiments described so far demonstrated that conse-
quences of matriptase expression in breast cancer cells may be cell
context dependent. Although we observed cell line-specific
consequences of matriptase overexpression on cell-cell interactions
and cytoskeletal organisation in 4T1 and MDA-MB-231 cells in
vitro, we saw little effect on their in vitro growth (Fig. 4D and
Fig. 5D). To assess the consequences of matriptase upregulation
on breast cancer cell growth in a more complex in vivo
microenvironment we grew the MDA-MB-231 and 4T1 cells
overexpressing matriptase and the respective control cells as
orthotopic xenografts after implantation into mammary fat pads of
CD1 nude mice. The clones displaying most similar growth
properties in vitro were selected for these in vivo experiments
(Empty A and MT-SP1 B for MDA-MB-231, Empty B and MT-
SP1 B for 4T1, see Fig. 4D and Fig. 5D for growth curves).
As illustrated in Fig. 7, in both cellular backgrounds the cells
overexpressing matriptase showed decreased growth compared to
the controls. This suggests that in breast cancer cells matriptase
may have some growth inhibitory functions in vivo. It is worth
noticing that in the case of 4T1 cells the reduction in the E-
cadherin level observed in vitro (Fig. 6B) was also evident in vivo
(Fig. S6).
Discussion
Proteases constitute about 2% of all proteins encoded in human
genome and they play essential roles in multiple biological
processes. Over the past decades overwhelming evidence for the
importance of proteases in cancer has accumulated in the
literature, but the high hopes for protease targeting strategies as
anticancer therapeutics has not yet fully materialised. In fact,
protease inhibitors have generally failed in clinical trials indicating
that more in depth understanding of the diversity and complexity
of the functions of proteases in cancer is required before effective
therapeutic strategies can be designed and implemented.
Matriptase is one of the proteases that attracted considerable
interest of cancer biologists in recent years. There is convincing
evidence linking matriptase to cancer in several systems (reviewed
in [3,14]), and matriptase is also a known activator of proteins with
established roles during carcinogenesis such as hepatocyte growth
factor (HGF) [11], urokinase-type plasminogen activator (uPA)
[11] and matrix metalloproteinase 3 [32]. Consequently, consider-
able effort was invested in the development of potential
matriptase-targetting therapeutics [15,16,17]. Despite this, the
significance of matriptase in several types of human cancer
remains unclear. Only a few published studies have tried to
address the importance of this protein in breast cancer and they
provided rather confusing results. In some studies, low matriptase
protein expression was independently predictive of poorer survival
(including poorer survival in node-negative group) [33], whereas in
others, high matriptase level was associated with poorer survival
among node-negative breast cancer cases [34]. In a further study,
no association was observed between the levels of matriptase
mRNA and survival [35]. Increased matriptase protein expression
was reported among advanced breast cancer cases in Chinese
women [36]. More recently, a coordinate overexpression of
matriptase mRNA, and mRNA’s for macrophage stimulating
protein and macrophage stimulating protein receptor Ron was
described to associate with metastasis and poor prognosis [37].
These rather conflicting data may reflect some natural variability
in human populations and/or result from differences in the
techniques/reagents used. They also strongly emphasise the need
for additional independent studies to increase our understanding
of the expression and roles of matriptase during breast
carcinogenesis.
Here, we have independently assessed the significance and role
of matriptase in breast cancer by evaluating protein expression
levels of matriptase in established breast cancer cell lines and
primary breast tumors using reverse phase protein arrays, and by
studying the behaviour of breast cancer cells engineered to stably
overexpress this protein.
The past studies on established cell lines demonstrated
deregulation of matriptase in breast cancer cells as compared to
non-transformed mammary epithelial cells [38]. In addition the
functions and regulation of matriptase in breast cancer cells seem
to be very complex and different from those in other cancer cell
types. For example, it has been shown that matriptase activation
and shedding with its cellular inhibitor HAI-1 is induced by steroid
sex hormones in human prostate cancer cells, but not in breast
cancer cells [39]. The activation of matriptase in breast cancer
cells can be triggered by multiple events including blood derived
factors and acidic pH [5,40]. It is also likely that matriptase has
protease-activity independent functions [2].
Our results show that there is considerable diversity of
matriptase protein expression levels among breast cancers, with
a substantial proportion of human breast cancers and established
breast cancer cell lines not expressing detectable amounts of
matriptase at all. The fact that significant proportion of breast
cancers does not express detectable levels of matriptase may have
direct consequences for further development and future use of
matriptase-targeting therapies. It is unlikely that such therapies will
be effective in breast cancer patients with negligible matriptase
expression in the tumor. Consequently, it may be advisable to pre-
screen patients for biomarkers of matriptase expression before
subjecting them to therapeutic intervention in clinical trials.
Interestingly the bioinformatic analysis indicated that the lack of
matriptase expression in breast cancers may be associated with
pre-translational rather than post-translational mechanisms. This
conclusion is supported by recent finding that elimination of
matriptase expression in MDA-MB-231 cells may be due to the
cleavage of its mRNA by miR-27b microRNA [41].
The observation that stable overexpression of matriptase in two
breast cancer cell lines was associated with diverse phenotypical
outcomes indicates that the actions of matriptase may be fine-
tuned for particular cellular context rather than follow universally
applicable patterns. This may reflect the fact that cellular
regulation and functions of matriptase are extremely complex
and still poorly understood [2]. For example, it has been reported
that HER2 signalling via the phosphatidylinositol 3-kinase
Matriptase in Breast Cancer
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pathway results in increased matriptase zymogen activity in
prostate cancer cells [42]. Our finding that matriptase expression
is correlated with HER2 status supports the notion that matriptase
function may be linked to HER2 signalling in cancer cells.
Another example of dependence of matriptase function on other
cellular signalling cascades is provided in the recent work of Szabo
et al., who demonstrated that genetic ablation of hepatocyte
growth factor receptor c-Met completely negates the oncogenic
potential of matriptase in matriptase expressing keratinocytes [43].
It is interesting to notice that in 4T1 cells overexpression of
matriptase was associated with reduction in cell-cell contacts and
downregulation of a major cell adhesion protein E-cadherin. The
role of matriptase in regulation of E-cadherin has been recently
proposed in Mardin-Darby canine kidney (MDCK) cells although
the precise mechanism of this regulation remains uncertain [44].
There is also accumulating evidence for the involvement of
matriptase in epithelial-mesenchymal transition (EMT) [44,45].
EMT is believed to play important role in tumor spread and
dawnregulation of E-cadherin associated with reduction in cell-cell
interactions represents one of the hallmarks of this process. Our
Figure 5. Properties of the 4T1 cells engineered to overexpress matriptase (MT-SP1 A, MT-SP1 B) and the respective control clones
(Empty A, Empty B). (A) Bright field images of the selected clones and parental cells. (B) Western blots performed on total cell lysates, and (C)
proteins precipitated from conditioned medium, using matriptase specific antibody. (D) In vitro growth curves for the selected clones and the
parental cell line. Although some ‘‘between-clone’’ variations were found (p,0.05) they were not associated with the presence or absence of MT-SP1
overexpression. (E) Representative fluorescence images of MT-SP1 B and Empty B cells stained with fluorescein-labelled phalloidin (actin
cytoskeleton) and DAPI (nuclei). Similar results were obtained with MT-SP1 A and Empty A clones respectively. Scale bar 10 mm.
doi:10.1371/journal.pone.0034182.g005
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data in 4T1 cells are certainly in agreement with those scenarios
suggesting that matriptase may play a role in breast cancer spread
and metastasis. This idea finds additional support in the fact that
knock down of matriptase in 4T1 cells has been reported to be
associated with decreased metastatic potential [46]. Although 4T1
cells represent a mouse cell line and there is no certainty that the
results obtained using this model can be extrapolated to human
cells, it is worth noticing, that published evidence exists that links
matriptase to regulation of cell adhesion in human cells.
Importantly, matriptase signalling has been implicated in a round-
ed phenotype similar to that we observed in 4T1 cells in a human
breast cancer cell line [8]. On the other side it is noteworthy that
in both MDA-MB-231 and 4T1 cells matriptase overexpression
was associated with moderately inhibited tumor growth in vivo.
These results contrast with growth promoting actions of matriptase
suggested in some other tumor types [15,32], and indicate that in
Figure 6. In vitro adhesive and migratory properties of selected 4T1 clones stably overexpressing matriptase (MT-SP1) and
respective control cells. (A) Migratory properties of indicated cells as determined in the Transwell migration assay. No statistically significant
differences between the clones were found (p.0.05). (B) Attachment strength of indicated clones as determined in the detachment assay. The results
obtained for MT-SP1 overexpressing clones were significantly different (p,0.005) from those obtained for control clones and parental cell line. (C)
Western blots illustrating E-cadherin expression in the indicated cell lines (left), and representative immunofluorescence pictures of E-cadherin
staining (green) in MT-SP1 overexpressing cells and control cells (right). (D) Western blots illustrating b-catenin expression in the indicated cell lines
(left), and representative immunofluorescence pictures of b-catenin staining (green) in MT-SP1 overexpressing cells and control cells (right). The
immunofluorescence data in panels (C) and (D) are for clones 4T1 Empty B and 4T1 MT-SP1 B respectively, but analogous results were obtained in 4T1
Empty A and 4T1 MT-SP1 A clones. Blue color represents DAPI staining (nuclei). The individual (not overlayed) images for b-catenin and DAPI
stainings presented in panel (D) are provided in Figure S4. Error bars in (A) and (B) represent standard errors. Scale bars 30 mm.
doi:10.1371/journal.pone.0034182.g006
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breast cancer matriptase may display both tumor promoting and
tumor suppressing activities.
Materials and Methods
Ethics statement
The study was approved by the Lothian Research Ethics
Committee (08/S1101/41). No informed consent (written or
verbal) was obtained for use of retrospective tissue samples from
the patients within this study, most of whom were deceased, since
this was not deemed necessary by the Ethics Committee, who
waived the need for consent.
All procedures involving animals were carried out in accordance
with UK Coordinating Committee on Cancer Research guidelines
by approved protocol (Home Office Project Licence no. 60/3576).
Protein extraction from frozen tissue and cell lines
Protein was extracted from 107 breast tumours treated within
the Edinburgh Breast Unit, all of which had pathological
confirmation of malignancy. Tumor material was placed in an
ice-cold flat bottomed soda-glass tube (50612mm) with 0.3 ml of
Lysis buffer (50 mM Tris pH 7.5; 5 mM EGTA pH 8.5; 150 mM
NaCl supplemented with protease inhibitors (Roche
11836153001), phosphatase inhibitors (Sigma P2850; P5726) and
aprotinin (Sigma A6279)). Samples were homogenised on ice at
full power for 2610sec (with a 30 sec interval between bursts to
allow the sample to cool down) using a Silverson homogeniser.
Resulting homogenates were transferred to pre-cooled microcen-
trifuge tubes and residual material recovered from the homo-
geniser with a further 260.3 ml of lysis buffer (total pooled volume
of each sample = 0.9 ml). Triton X-100 was added to each sample
(9 ml/0.9 ml) before centrifuging at 13,000 g for 30 min at 4uC
after which supernatants were transferred to fresh microcentrifuge
tubes. Total protein concentrations were determined by BCA
assay (Thermo Scientific, #23235) and normalised at 2 mg/ml.
The cell line lysates were prepared in a similar way using the same
lysis buffer.
Reverse phase protein arrays (RPPA)
Denatured and reduced protein lysates were spotted onto LI-
COR (LI-COR Biosciences, Nebraska, USA) nitrocellulose-coated
glass slides as previously described [47]. Three replicates were
spotted per sample in five two-fold dilutions. Slides were hydrated
in Li-Cor blocking buffer for 1 hour (LI-COR Biosciences,
Nebraska, USA), and then incubated with previously optimised
primary antibodies overnight at 4uC in a sealed box containing
a damp paper towel. The following day slides were washed in
PBS/T at room temperature for 5 minutes (63) before incubating
with far-red fluorescently-labelled secondary antibodies diluted in
Li-Cor Odyssey Blocking Buffer (1 ml/2 ml) at room temperature
for 45 mins with gentle shaking. Slides were then washed in excess
PBS/T (63)/PBS (63) and allowed to air dry before reading on
a Li-Cor Odyssey scanner at 680 nm and 780 nm.
RPPA analysis was performed using MicroVigene RPPA
analysis module (VigeneTech, Carlisle, MA, USA). Spots were
quantified by accurate single segmentation, with actual spots signal
boundaries determined by the image analysis algorithm. Each spot
intensity was quantified by measuring the total pixel intensity of
the area of each spot (volume of spot signal pixels), with
background subtraction of 2 pixels around each individual spot.
The mean of the replicates was used for normalization and curve
fitting. Curve fitting was performed using four parameter logistical
non-linear regression using a joint estimation approach.
Bioinformatics
Expression data from Neve et al. [23] was downloaded from
Array Express (E-TABM-157) and expression values derived using
the RMA algorithm (Bioconductor affy package) combined with
an updated microarray annotation (U133A, Ensembl gene CDF
version 11 [24]).
Plasmid vectors
pHygpbactin-EcoRV-IRES-mCherry plasmid was created by
introducing a cassette containing chicken bactin promoter, EcoRV
restriction site, internal ribosome entry site and mCherry coding
sequence into the pTKHyg plasmid backbone (Clontech). The
pHygpbactin-Matriptase-IRES-mCherry plasmid was subsequent-
ly generated by introducing a PCR amplified human matriptase
open reading frame into the EcoRV site of pHygpbactin-EcoRV-
Figure 7. In vivo growth characteristics of indicated MDA-MB-
231 and 4T1 cells engineered to stably overexpress matriptase
(MT-SP1) and the respective control clones. The cells were
injected into mammary fat pads of CD1 nude mice and grown as
described in the materials and methods section. There were at least five
animals in each group. (A) Growth curves of MDA-MB-231 MT-SP1 B
(black circles) and MDA-MB-231 Empty A (white circles) clones. The MT-
SP1 overexpressing cells grew significantly slower than the empty
vector control cells (p = 0.003 on day 27). (B) Growth curves for 4T1 MT-
SP1 B (black circles) and 4T1 Empty B (white circles) clones. The MT-SP1
overexpressing cells grew slower than the empty vector control cells
although this was not statistically significant (p = 0.107 on day 16 and
p= 0.187 on day 20). Error bars represent standard errors.
doi:10.1371/journal.pone.0034182.g007
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IRES-mCherry vector. pHygpbactin-Matriptase-IRES-mCherry
and pHygpbactin-EcoRV-IRES-mCherry plasmids were used to
generate MT-SP1 and Empty clones, respectively.
Cell culture, transfections, and selection of stable cell
lines
The MDA-MB-231 [25], 4T1 [26] and other cells [27] were
grown in DMEM (Gibco/Invitrogen). The medium was supple-
mented with 10% fetal calf serum, 100 U/ml penicillin and
100mg/ml streptomycin. Transfections were performed using
Amaxa Nucleofector technology (Lonza) accordingly to the
manufacturer’s protocols. Stable cell lines were selected using
previously described protocol [48]. Hygromycin B (Calbiochem,
cat. no. 400052) at 250 mg/ml was used as the selection agent and
mCherry signal was utilised for flow cytometric sorting of positive
cells after selection.
Protein precipitation from the conditioned medium
To analyse the presence of matriptase in the conditioned media
of engineered MDA-MB-231 and 4T1 cells, the cells were seeded
on day 0 into 10 cm tissue culture dishes (TPP, cat. no. 93100) to
reach ,90% confluency the next day (day 1). On day 1 the cells
were rinsed with 10 ml of serum free DMEM and overlayed with
5 ml of serum free Optimem with Glutamax (Gibco/Invitrogen
cat. no. 51985). After 24 h the medium was transferred into 15 ml
falcon tube and spun down 3 min at 1100 RPM to pellet any
potential floating cells. The supernatant was transferred into 50 ml
falcon tube and precipitated using 36 ml of 100% ethanol at –
20uC for 48 h. Subsequently the resulted precipitate was pulled
down by centrifugation for 1h at 4600 RPM (4uC) in the Sorvall
Legend RT centrifuge. The supernatant was decanted and the
pellet rinsed with 20 ml of 90% ethanol (220uC). This was
followed by centrifugation for 30 min at 4600RPM. The
supernatant was removed and the pellet dried. Subsequently
200 ml of 3xSDS-Samble Buffer + b mercaptoethanol was added
to extract the pelleted proteins. After short incubation (,5 min)
the samples were transferred to 1.5 ml eppendorf tubes and
incubated for 3 min at 100uC. They were subsequently frozen and
stored at 220uC until SDS-PAGE and western blotting. 20 ml of
each sample was loaded pro lane of 10% gel.
Antibodies, Gel Electrophoresis and Western Blot
Analysis
SDS-PAGE and western blotting were performed as previously
described [49]. The following primary antibodies were used:
rabbit polyclonal anti matriptase/ST14 (Bethyl Laboratories, cat.
no. A300–221A), rabbit monoclonal anti Src (Cell Signaling, cat.
no. 2109), rabbit polyclonal anti phospho-Src (Tyr416) (Cell
Signaling, cat. no. 2101), mouse monoclonal anti FAK (Upstate
biotechnology, cat. no. 05–537), rabbit polyclonal anti phosphor-
FAK (Tyr397) (Invitrogen cat. no. 44624G), mouse monoclonal
anti E-cadherin (BD Biosciences, cat. no. 610182), mouse
monoclonal anti b-catenin (BD Transduction Laboratories, cat.
no. 610154), polyclonal rabbit anti c-tubulin (Sigma-Aldrich, cat.
no. T3559).
In vitro growth assay
To assess in vitro proliferation the cells were plated out at 16105
cells/4ml of medium per well in six-well plates (Costar 3516,
Corning). They were subsequently counted every day for a period
of six days. The medium from the well was collected, the adherent
cells were trypsinized using 1ml of 0.05% trypsin solution and
added to the medium collected from the well. The cells were spun
down for 5 min at 1100 RPM in a standard table top centrifuge,
resuspended in PBS (250 ml day 1, 500 ml day 2, 1 ml day 3, 3 ml
day 4, 5 ml days 5 and 6) and counted using haemocytometer.
Three independent experiments (each consisting of three in-
dependent repeats counted in duplicates) were performed and the
data from a representative experiment are displayed. Potential
differences between different clones at different time points were
analysed using series of student’s T-tests.
Cell detachment assay
For cell detachment assay 36106 cells/well were seeded in 6well
plates (Corning) in 4 ml medium. After 20 h the cells were washed
twice with 1.5 ml of PBS and 1.5 ml of PBS/EDTA was added.
The cells were subjected to mechanical stress by rotatory shaking
(level 6 on the Heidolph rotomax 120 shaker). After 15min the
detached cells were collected by transfering PBS/EDTA contain-
ing detached cells into a universal tube containing 3 ml of
medium. The attached cells were trypsynized using 1 ml of 0.05%
trypsin solution and transferred into a separate universal tube
containing 3 ml of medium. Both the detached cells and the
attached cells were spun down for 5 min at 1100 RPM in
a standard table top centrifuge and their numbers estimated using
haemocytometer after resuspension in 500 ml of PBS. The
presented data are based on three independent experiments each
containing two repeats counted in duplicates. The differences
between the groups were analysed using student’s T-tests.
Transwell migration assay
For transwell cell migration assays 16105 cells in 100 ml
DMEM containing 1%FCS were placed in the top part of the
6.5 mm diameter, 8.0 mm pore size transwell chamber (Corning,
Lowell, MA, USA cat. no. 3422), the bottom part was filled with
600 ml of DMEM containing 10%FCS. The cells were allowed to
migrate for 16 hrs. They were subsequently fixed in ice cold 100%
methanol and the nuclei of cells that migrated through the
membrane were stained with propidium iodide (10 mg/ml in PBS).
The number of migrated cells was estimated by counting the cells
in 6 randomly selected fields of view using fluorescent microscope
(406 objective). The presented data are based on three
independent experiments each containing two repeats. The
differences between the groups were analysed using student’s T-
tests.
Immunofluorescence
For immunofluorescence studies the cells were seeded on glass
coverslips in 12 well tissue culture plates (TPP, cat. no. 92012).
After 24–30 hrs the cells were rinsed twice with PBS, fixed with
3.7% formaldehyde and stained with appropriate antibodies using
previously described procedures [50]. The same anti E-cadherin,
b-catenin, FAK and phospho-Src antibodies as for western
blotting were used. The secondary antibodies were Alexa Fluor
488 labeled anti mouse (Invitrogen, cat. no. A11029) or anti rabbit
(Invitrogen, cat. no. A11034) immunoglobulines. After staining the
coverslips were mounted on microscopic slides using Vectashield
with DAPI (Vector Laboratories cat. no. H-1200) and images were
acquired with FV1000 confocal microscope and 63x objective as
previously described [49].
Orthotopic tumor xenografts
For in vivo growth analysis 16106 cells in 50 ml of 1:1 HBSS/
matrigel mixture (Gibco cat no. 14025/BD Biosciences cat. no.
354234) were injected into the mammary fat pads of 6–8 week-old
female CD1 nude mice (Charles River). Mice were housed in an
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individually ventilated caging system on a 12-hour light/dark
environment maintained at constant temperature and humidity.
Tumor measurements were performed twice a week using
a calliper. Tumor volume was defined as length x width2/2.
There were seven animals in each empty vector control and MT-
SP1 overexpressing group for MDA-MB-231 cells and five animals
per group for 4T1 cells. Student’s T-tests were used to statistically
evaluate the data.
Supporting Information
Figure S1 Analysis of matriptase (MT-SP1) protein
levels in indicated cell lines determined using standard
western blotting approach. Tubulin and Ponceau stainings
were performed as loading controls.
(PDF)
Figure S2 Comparison of in vitro migratory properties
(A) and attachment strength (B) in the indicated MDA-
MB-231 clones and the parental cell line. (See materials and
methods for details.). No statistically significant differences
between the clones were found with respect to in vitro migratory
properties (p.0.05). Although some ‘‘between-clone’’ variations
were found (p,0.05) with respect to attachment strength, they
were not associated with the presence or absence of MT-SP1
overexpression. Error bars represent standard errors.
(PDF)
Figure S3 Matriptase (MT-SP1) protein levels in the 4T1
MT-SP1 A cells and in the subpopulation of these cells
that spontaneously reverted to a ‘‘flat’’ morphology. (A)
Bright field image of the initial 4T1 MT-SP1 A cells. (B) Bright
field image of the ‘‘flat’’ morphology subpopulation established
from 4T1 MT-SP1 A clone. (C) Western blot showing matriptase
levels in the initial 4T1 MT-SP1 A cells (Initial) and in 4T1 MT-
SP1 A cells that reverted to a ‘‘flat’’ phenotype (Reverted). Actin
represents the loading control. Note that we purposefully
overloaded the ‘‘Reverted’’ line to underline the decrease in
matriptase level. The 4T1 MT-SP1 A cells that reverted to a ‘‘flat’’
phenotype were established after multiple (.20) passages. They
were split using 0.05% trypsin solution in PBS after a short wash
(,1 min) with low concentration (0.025%) trypsin in PBS to
remove less adherent cells. The cells were split 1:16 every three
days.
(PDF)
Figure S4 Focal adhesion kinase and c-Src in 4T1 cells
with stable matriptase (MT-SP1) overexpression and
control cells. (A) Western blots illustrating total Src and P-
Src(Y416) levels in the indicated cell lines (left), and representative
immunofluorescence pictures of P-Src staining (green) in MT-SP1
overexpressing cells and control cells (right). (B) Western blots
illustrating total FAK and P-FAK(Y397) levels in the indicated cell
lines (left), and representative immunofluorescence pictures of
FAK staining (green) in MT-SP1 overexpressing cells and control
cells (right). The immunofluorescence data are for clones 4T1
Empty B and 4T1 MT-SP1 B respectively, but analogous results
were obtained in 4T1 Empty A and 4T1 MT-SP1 A clones. Blue
color represents DAPI staining (nuclei). Scale bars 10 mm.
(PDF)
Figure S5 Individual images for b-catenin (top) and
DAPI (bottom) stainings in 4T1 cells overexpressing MT-
SP1 (right) or control cells transfected with empty vector
(left). The same images are presented as overlays in Fig. 6D.
Scale bar 30 mm.
(PDF)
Figure S6 Immunohistochemistry for E-cadherin in
tumor sections derived from 4T1 Empty (A), and 4T1
MT-SP1 (B), orthotopic xenografts. (C) and (D) repre-
sent ‘‘no primary antibody’’ controls for (A) and (B)
respectively. Representative pictures were selected. The details
of the immunohistochemistry are provided in the ‘‘Immunohisto-
chemistry protocol’’ section of this figure.
(PDF)
Table S1 Clinical data associated with the set of 107
primary tumor samples used in this study.
(PDF)
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